Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T60345
|
||||
Target Name |
T-cell surface glycoprotein CD3
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9:204.0, 556; ICD10: C91.0, C92.0] | ||||
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | |||||
Non-hodgkin's lymphoma [ICD10: C85] | |||||
Type 1 diabetes [ICD9: 250; ICD10: E10] | |||||
BioChemical Class |
Antigen
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Blinatumomab | Drug Info | Approved | Acute lymphoblastic leukemia | [889388], [889412] |
Otelixizumab | Drug Info | Phase 2 | Type 1 diabetes | [543149], [547674] | |
CD20Bi aATC | Drug Info | Phase 1 | Non-hodgkin's lymphoma | [544343] | |
MGD006 | Drug Info | Phase 1 | Acute lymphoblastic leukemia; Acute myeloid lymphoma | [544458], [889399] | |
References | |||||
Ref 543149 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8458). | ||||
Ref 544343 | CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. | ||||
Ref 544458 | A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. | ||||
Ref 547674 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018350) | ||||
Ref 889388 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.